Indoco Remedies · NSE: INDOCO · BSE: 532612
Q4 FY22 results · Jan–Mar 2022
Indoco Remedies reported revenue from operations of ₹409.13 crore (up 34.1% from Q4 FY21) and net profit of ₹40.45 crore (up 61.8% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 409.13 | 305.14 | +34.1% | 358.00 | +14.3% |
| Other income | 0.30 | 1.98 | −84.8% | 0.16 | +87.5% |
| Total income | 409.43 | 307.12 | +33.3% | 358.16 | +14.3% |
| Profit before tax | 59.75 | 33.56 | +78.0% | 50.58 | +18.1% |
| Net profit for the period | 40.45 | 25.00 | +61.8% | 32.99 | +22.6% |
| EPS, basic (₹) | 4.39 | 2.71 | +62.0% | 3.58 | +22.6% |
| Net margin (%) | 9.9 | 8.2 | 9.2 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 408.88 | 304.85 | +34.1% | 357.76 | +14.3% |
| Other income | 0.29 | 1.97 | −85.3% | 0.16 | +81.2% |
| Total income | 409.17 | 306.82 | +33.4% | 357.92 | +14.3% |
| Profit before tax | 59.68 | 33.45 | +78.4% | 50.53 | +18.1% |
| Net profit for the period | 40.37 | 24.91 | +62.1% | 32.97 | +22.4% |
| EPS, basic (₹) | 4.38 | 2.70 | +62.2% | 3.58 | +22.3% |
| Net margin (%) | 9.9 | 8.2 | 9.2 |
Consolidated
- Filed with BSE
- 17 May 2022, 17:07 IST
- Board meeting
- 17 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 May 2022, 17:07 IST
- Board meeting
- 17 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE